Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System-Reference-Cited by-同舟云学术

Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System

Published:2019-03-29 Issue:2 Volume:14 Page:205-221
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Raschi Emanuel^ORCID,Mazzarella Alessandra,Antonazzo Ippazio Cosimo,Bendinelli Nicolò,Forcesi Emanuele,Tuccori Marco,Moretti Ugo,Poluzzi Elisabetta,De Ponti Fabrizio

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11523-019-00632-w.pdf

Reference63 articles.

1. Clarke JM, George DJ, Lisi S, Salama AKS. Immune checkpoint blockade: the new frontier in cancer treatment. Targ Oncol. 2018;13:1–20.

2. Martin-Liberal J, Hierro C, de Ochoa OM, Rodon J. Immuno-oncology: the third paradigm in early drug development. Targ Oncol. 2017;12:125–38.

3. Hoos A. Development of immuno-oncology drugs—from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016;15:235–47.

4. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2:1346–53.

5. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749–55.

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigating drug-induced urinary retention: a pharmacovigilance analysis of FDA adverse event reports from 2004 to 2024;Expert Opinion on Drug Safety;2024-09-13

2. Phagolysosomal resistance hypothesized to be a danger signal;Scandinavian Journal of Immunology;2024-08-13

3. Assessment of Neurologic Safety Profile of Immune Checkpoint Inhibitors: Evaluation of Adverse Drug Reaction Reports;Current Drug Safety;2024-08

4. Immune‐related adverse events of antibody‐based biological medicines in cancer therapy;Journal of Cellular and Molecular Medicine;2024-07

5. Vitreoretinal Traction Syndrome, Nitrituria and Human Epidermal Growth Factor Receptor Negative Might Occur in the Aromatase-Inhibitor Anastrozole Treatment;International Journal of Clinical Practice;2024-05-10